Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1Breast 1

Conditions

Brain Neoplasms 2Neoplasm Metastasis 1Glioma 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Radiosurgery 33Radiotherapy 19Temozolomide 16Magnetic Resonance Spectroscopy 12Surgical Procedures, Operative 7Cyclophosphamide 7trastuzumab deruxtecan 4temsirolimus 4Sunitinib 4Specimen Handling 4Mental Status and Dementia Tests 4motexafin gadolinium 3fludarabine phosphate 3fludarabine 3aldesleukin 3Trastuzumab 3Pemetrexed 3Fluorodeoxyglucose F18 3Erlotinib Hydrochloride 3Dexamethasone 3Capecitabine 3Bevacizumab 3pembrolizumab 2entrectinib 2efaproxiral 2Vinorelbine 2Topotecan 2Sorafenib 2Radiotherapy, Intensity-Modulated 2Quality of Life 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × peginterferon alfa-2a × CNS × Clear all
NCT00227656 2012-12-11

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡